
|Articles|March 1, 2016
- Pharmaceutical Executive-03-01-2016
- Volume 36
- Issue 3
Pharmaceutical Executive, March 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Beyond 2020: Building Strategic Coherence in the New Health Economyalmost 10 years ago
What Errors Do We Miss in Clinical Trials?almost 10 years ago
Data Disclosure: Sealing the Error Envelopealmost 10 years ago
Vaccines 2016: Big Bets for Global Threatsalmost 10 years ago
Drug Delivery Roundtable: More than the Pillalmost 10 years ago
Orphans of the Stormalmost 10 years ago
Country Report: The NetherlandsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
AstraZeneca Reaches $2 Billion License Agreement with Jacobio Pharma for Pan-KRAS Inhibitor
2
JP Morgan 2026 Preview: Eli Lilly Seeks Bounce Back
3
Alnylam Announces $250 Million Investment in Massachusetts Facility
4
Pharmaceutical Executive Daily: Nine New Additions to TrumpRx
5




